Scarica l'app Stockscreener
49.78
0.65%
0.32
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTCT Giù?
Forum
Previsione
Precedente Chiudi:
$49.46
Aprire:
$49.35
Volume 24 ore:
768.91K
Relative Volume:
0.67
Capitalizzazione di mercato:
$3.95B
Reddito:
$900.66M
Utile/perdita netta:
$-453.20M
Rapporto P/E:
-8.3805
EPS:
-5.94
Flusso di cassa netto:
$-274.19M
1 W Prestazione:
+1.90%
1M Prestazione:
+11.27%
6M Prestazione:
-1.56%
1 anno Prestazione:
+40.94%
Intervallo 1D:
$48.86
$50.70
Intervallo di 1 settimana:
$48.27
$51.03
Portata 52W:
$30.41
$58.38
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Nome
Ptc Therapeutics Inc
Settore
Industria
Telefono
(908) 222-7000
Indirizzo
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Confronta PTCT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
49.78 | 3.93B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-17 | Iniziato | Truist | Buy |
| 2025-05-09 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-05-07 | Aggiornamento | Citigroup | Sell → Neutral |
| 2025-03-11 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Iniziato | Scotiabank | Sector Perform |
| 2024-12-13 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-09-04 | Iniziato | Robert W. Baird | Outperform |
| 2024-08-26 | Ripresa | UBS | Buy |
| 2024-05-20 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-10-30 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Downgrade | Citigroup | Neutral → Sell |
| 2023-10-06 | Downgrade | Truist | Buy → Hold |
| 2023-09-18 | Downgrade | Citigroup | Buy → Neutral |
| 2023-09-15 | Downgrade | Raymond James | Outperform → Underperform |
| 2023-03-17 | Iniziato | SVB Securities | Market Perform |
| 2022-12-14 | Iniziato | Goldman | Sell |
| 2022-09-12 | Iniziato | Jefferies | Buy |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2022-04-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-03-29 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-01-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-11-30 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-10-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-04-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-02-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-05-13 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Iniziato | Bernstein | Outperform |
| 2018-10-03 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-06-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Downgrade | JP Morgan | Neutral → Underweight |
Mostra tutto
Ptc Therapeutics Inc Borsa (PTCT) Ultime notizie
Using economic indicators to assess PTC Therapeutics Inc. potentialQuarterly Risk Review & High Win Rate Trade Alerts - Newser
Key metrics from PTC Therapeutics Inc.’s quarterly dataJuly 2025 Drop Watch & Consistent Growth Stock Picks - Newser
Using Python tools to backtest PTC Therapeutics Inc. strategiesMarket Sentiment Review & Fast Gain Stock Trading Tips - Newser
Is now a turning point for PTC Therapeutics Inc.2025 Valuation Update & Community Supported Trade Ideas - Newser
Is a relief rally coming for PTC Therapeutics Inc. holdersJuly 2025 Breakouts & Reliable Volume Spike Alerts - Newser
Opinion | The Two Faces of the FDA - The Wall Street Journal
Using Bollinger Bands to evaluate PTC Therapeutics Inc.July 2025 Sector Moves & AI Driven Stock Movement Reports - Newser
Invesco Ltd. Has $15.81 Million Stake in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics Inc. stock outlook for YEARQuarterly Earnings Report & Weekly Consistent Profit Watchlists - Newser
What technical models suggest about PTC Therapeutics Inc.’s comebackGlobal Markets & Consistent Profit Trading Strategies - Newser
What earnings revisions data tells us about PTC Therapeutics Inc.Chart Signals & Weekly High Return Stock Opportunities - Newser
PTC Therapeutics Inc. stock retracement – recovery analysisMarket Growth Report & Fast Moving Stock Trade Plans - Newser
Is PTC Therapeutics Inc. still worth holding after the dipJuly 2025 Volume & Daily Entry Point Alerts - Newser
Technical signs of recovery in PTC Therapeutics Inc.2025 Retail Activity & Low Drawdown Trading Techniques - Newser
Smart tools for monitoring PTC Therapeutics Inc.’s price action2025 Market Trends & Low Risk High Win Rate Stock Picks - Newser
Will earnings trigger a reversal in PTC Therapeutics Inc.Portfolio Value Report & Risk Controlled Daily Trade Plans - Newser
How moving averages guide PTC Therapeutics Inc. tradingJuly 2025 Recap & High Accuracy Investment Entry Signals - Newser
What recovery options are there for PTC Therapeutics Inc.July 2025 Catalysts & Reliable Entry Point Trade Alerts - Newser
Price action breakdown for PTC Therapeutics Inc.2025 Breakouts & Breakdowns & Risk Managed Investment Entry Signals - Newser
Analyzing drawdowns of PTC Therapeutics Inc. with statistical tools2025 Investor Takeaways & Safe Entry Momentum Tips - Newser
What momentum shifts mean for PTC Therapeutics Inc.Earnings Summary Report & Risk Managed Investment Signals - Newser
T. Rowe Price Investment Management Inc. Purchases New Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
What MACD and RSI say about PTC Therapeutics Inc.July 2025 Reactions & Accurate Buy Signal Alerts - Newser
How to use a screener to detect PTC Therapeutics Inc. breakoutsM&A Rumor & High Conviction Trade Alerts - Newser
Best data tools to analyze PTC Therapeutics Inc. stockMarket Performance Summary & Capital Protection Trading Alerts - Newser
What makes PTC Therapeutics Inc. stock price move sharply getLinesFromResByArray error: size == 0 - 더경남뉴스
Real time social sentiment graph for PTC Therapeutics Inc.Portfolio Return Report & Community Trade Idea Sharing - Newser
Can machine learning forecast PTC Therapeutics Inc. recoveryJuly 2025 Movers & Reliable Entry Point Alerts - Newser
Institutional scanner results for PTC Therapeutics Inc.2025 Dividend Review & Weekly Top Gainers Alerts - Newser
What machine learning models say about PTC Therapeutics Inc.2025 Market Trends & Verified Trade Idea Suggestions - Newser
Is PTC Therapeutics Inc. Forming a Bottom Pattern getLinesFromResByArray error: size == 0 - newsyoung.net
Applying Elliott Wave Theory to PTC Therapeutics Inc.July 2025 Review & Low Risk High Win Rate Stock Picks - Newser
What is William Blair's Forecast for PTCT FY2025 Earnings? - MarketBeat
Key resistance and support levels for PTC Therapeutics Inc.Portfolio Growth Summary & Weekly Sector Rotation Insights - Newser
PTC Therapeutics to Host Conference Call with Truist on August 25 - AInvest
Wellington Management Group LLP Purchases 632,049 Shares of PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics Surges to 480th in Market Activity with $190M Volume as Shares Dip 0.33% Amid FDA Scrutiny and Analysts Split on Valuation Outlook - AInvest
PTC Therapeutics rare disease therapy rejected by FDA - MSN
PTC Therapeutics Inc. Shows Risk Reward Favoring Upside2025 Macro Impact & Step-by-Step Swing Trade Plans - beatles.ru
What to expect from PTC Therapeutics Inc. in the next 30 daysQuarterly Profit Report & Real-Time Volume Analysis - Newser
Ptc Therapeutics shares rise 1.05% premarket after Biogen and Eisai launch Alzheimer's disease treatment in EU. - AInvest
Is PTC Therapeutics Inc. trending in predictive chart modelsJuly 2025 Review & AI Enhanced Trade Execution Alerts - Newser
Multi asset correlation models including PTC Therapeutics Inc.July 2025 Patterns & Free Community Consensus Stock Picks - Newser
Ptc Therapeutics Inc Azioni (PTCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
8.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):